Eli Lilly Vs. Hims & Hers In DTC Weight Loss Market? - There Is Only One Winner
Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.
Fierce Healthcare20h
DTC obesity med market heats up: Eli Lilly taps knownwell, Hims & Hers adds new weight loss meds to platform
Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...
‘Hold the Phone,’ Says Morgan Stanley on Hims & Hers Health Stock (HIMS)
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Health Care Roundup: Market Talk
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...
Investor's Business Daily on MSN22h
Sarepta Plunges After EMA Puts Gene Therapy Studies On Hold Following Teen's Death
Sarepta stock plunged Thursday after European officials put all studies of the company's gene therapy, Elevidys, on hold.
Analysts Stay Cautious on HIMS Stock amid Core Business Uncertainty
Hims & Hers Health Inc. (HIMS) is facing increased skepticism from investors and analysts over the sustainability concerns of ...
Zacks.com on MSN14h
Novo Nordisk (NVO) Stock Moves -1.67%: What You Should Know
Novo Nordisk (NVO) ended the recent trading session at $67.10, demonstrating a -1.67% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily loss of ...